ESMO 2023 – butterflies for J&J
Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
World Lung 2023 – Flaura2 leaves a gap open for J&J
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Lung cancer switch does the job for Black Diamond
First data with the biotech’s new EGFR project prompts a 236% share price bump.
ASCO 2023 – China’s Dizal claims broad coverage with a super-Tagrisso
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
